<DOC>
	<DOCNO>NCT00530868</DOCNO>
	<brief_summary>This purpose trial show combination Avastin hormone therapy effective hormone therapy alone treatment breast cancer .</brief_summary>
	<brief_title>Comparing Letrozole Given Alone Letrozole Given With Avastin Post-Menopausal Women Breast Cancer</brief_title>
	<detailed_description>Preclinical clinical data demonstrate up-regulation tumor cell VEGF important mechanism subvert estrogen dependence hormone responsive breast cancer result reduce therapy response tumor resistance hormonal therapy ; thus , hypothesize combination anti-VEGF agent ( Avastin , anti-VEGF monoclonal antibody ) hormonal therapy effective hormonal therapy alone treatment breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>All patient must meet follow criterion eligible study entry : Pathologically confirm invasive ductal carcinoma invasive lobular carcinoma breast , T2T3 / T4ac / N02 / M0 , positive estrogen and/or progesterone receptor , Her2neu negative . Patients inflammatory breast cancer include ( T4d ) . Patients previously treat patient measurable disease patient metastatic disease exclude . Give write informed consent prior study specific screening procedure , understand patient right withdraw study time , without prejudice . Patients must postmenopausal , define one following : Patients &gt; 50 year age spontaneous menses least 12 month , Bilateral oophorectomy Be ambulatory ( outpatient ) ECOG PS &lt; 1 . Patients must measurable disease mammogram and/or breast ultrasound ( special case dedicate breast MRI may clinically indicate ) . The target lesion must previously irradiate . No prior chemotherapy . Patients must adequate organ marrow function define follow : absolute neutrophil count &gt; 1,500/mm3 , hemoglobin &gt; 8.0 g/dl , platelet &gt; 75,000/mm3 , total bilirubin &lt; 2 mg/dl , serum creatinine &lt; 2 mg/dl , Transaminases ( AST , ALT ) may 2 x institutional upper limit normal . In addition &lt; 1 gr protein 24 hr urine collection urine protein/creatinine ratio &lt; 1.0 . No life threaten parenchymal disease rapidly progress disease warrant cytotoxic chemotherapy . Hypertension must control ( &lt; 150/100 mmHg ) . Ejection Fraction &gt; 50 % echocardiogram . ( LVEF great 75 % baseline review and/or test repeat may falsely elevate ) . No history thrombosis previous 12 month . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study sponsorinvestigator Bevacizumab cancer study . Uncontrolled high blood pressure ( &gt; 150/100 mmHg ) . Unstable angina New York Heart Association ( NYHA ) Grade III great congestive heart failure History myocardial infarction unstable angina within 12 month History stroke TIA within 12 month Clinically significant peripheral vascular disease History bleed disorder Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure ( exclude fine needle aspiration core biopsy ) within 5 day prior Day 0 Pregnant ( positive pregnancy test ) lactate Urine protein : creatinine ratio great equal 1.0 screening patient demonstrate &gt; 1 gr protein 24 hr urine collection within 4 week prior study entry participate trial . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Unwilling unable comply protocol duration study . Psychiatric illness/social situation would limit compliance study requirement . History another malignancy within last five year except nonmelanoma skin cancer carcinoma insitu uterine cervix . Patients metastatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hormonal antibody therapy breast cancer</keyword>
	<keyword>Hormonal therapy breast cancer</keyword>
	<keyword>Antibody therapy breast cancer</keyword>
</DOC>